OmniSeq

Labcorp announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting held June 4-8. Be sure to check out the presentation on June 7, 10am ET which includes the introduction of OmniSeq’s newly NYS CLEP approved assay, , OmniSeq INSIGHTa pan-cancer, tissue-based sequencing test for patients with late-stage solid tumor cancers. https://www.businesswire.com/news/home/20210602006067/en/ L...abcorp OmniSeq American Society of Clinical Oncology #PrecisionMedicine #oncology See more

OmniSeq participates in a multi-lab evaluation of targeted sequencing oncopanels employing FDA-led SEQC2 references to provide best practices for oncopanel sequencing. Congrats to OmniSeq's Sean Glenn, Jeffrey Conroy and Blake Burgher! "Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions." Download it here:... https://genomebiology.biomedcentral.com//s13059-021-02315-0 #precisionmedicine #oncology

IN PRESS! Check out OmniSeq's contribution to the understanding of the the adverse effects of visceral obesity in NSCLC patients through analysis of tumor transcriptome and immune microenvironment. Congrats to Sarabjot Pabla, Robert Seager and Jeffrey Conroy! "Visceral Obesity Promotes Lung Cancer Progression Towards Resolution of the Obesity Paradox in Lung Cancer" Download it here:... https://www.jto.org/article/S1556-0864(21)02171-7/pdf See more

Some nice coverage on our NYS CLEP approval of OmniSeq INSIGHT by Buffalo Business First https://www.bizjournals.com///omniseq-new-cancer-test.html #PrecisionMedicine #oncology